

# DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

October 2009

Vol. 37, No. 10

## CONTENTS

### SHORT COMMUNICATIONS

Expression and Characterization of Functional Dog Flavin-Containing Monooxygenase 3. *Andrew J. Lickteig, Rochelle Riley, Roger J. Melton, Beverly A. Reitz, H. David Fischer, and Jeffrey C. Stevens* . . . . . **1987**

Allele and Genotype Frequencies of *Cytochrome P450 2B6* Gene in a Mongolian Population. *Jagdasuren Davaalkham, Tsunefusa Hayashida, Kiyoto Tsuchiya, Hiroyuki Gatanaga, Dulmaa Nyamkhuu, and Shinichi Oka* . . . . . **1991**

Presystemic Elimination of Trichloroethylene in Rats Following Environmentally Relevant Oral Exposures. *Y. Liu, M. G. Bartlett, C. A. White, S. Muralidhara, and J. V. Bruckner* . . . . . **1994**

### ARTICLES

Functional Characterization of Low-Prevalence Missense Polymorphisms in the UDP-Glucuronosyltransferase 1A9 Gene. *Kristine C. Olson, Ryan W. Dellinger, Qing Zhong, Dongxiao Sun, Shantu Amin, Thomas E. Spratt, and Philip Lazarus* . . **1999**

Identification of Finasteride Metabolites in Human Bile and Urine by High-Performance Liquid Chromatography/Tandem Mass Spectrometry. *Anna Lundahl, Hans Lennernäs, Lars Knutson, Ulf Bondesson, and Mikael Hedeland* . . . . . **2008**

The Pneumotoxin 3-Methylindole Is a Substrate and a Mechanism-Based Inactivator of CYP2A13, a Human Cytochrome P450 Enzyme Preferentially Expressed in the Respiratory Tract. *Jaime D'Agostino, Xiaoliang Zhuo, Mohammad Shadid, Daniel G. Morgan, Xiuling Zhang, W. Griffith Humphreys, Yue-Zhong Shu, Garold S. Yost, and Xinxin Ding* . . **2018**

Multiple Efflux Pumps Are Involved in the Transepithelial Transport of Colchicine: Combined Effect of P-Glycoprotein and Multidrug Resistance-Associated Protein 2 Leads to Decreased Intestinal Absorption Throughout the Entire Small Intestine. *Arik Dahan, Hairat Sabit, and Gordon L. Amidon* . . . . . **2028**

Modulation of Bile Acid Metabolism by 1 $\alpha$ -Hydroxyvitamin D<sub>3</sub> Administration in Mice. *Shigeru Nishida, Jun Ozeki, and Makoto Makishima* . . . . . **2037**

In Vitro Inhibition and Induction of Human Liver Cytochrome P450 Enzymes by Milnacipran. *Brandy L. Paris, Brian W. Ogilvie, Julie A. Scheinkoenig, Florence Ndikum-Moffor, Remi Gibson, and Andrew Parkinson* . . . . . **2045**

Absorption, Disposition, Metabolic Fate, and Elimination of the Dopamine Agonist Rotigotine in Man: Administration by Intravenous Infusion or Transdermal Delivery. *Willi Cawello, Marina Braun, and Hilmar Boekens* . . . . . **2055**

Investigation of the Influence of *CYP1A2* and *CYP2C19* Genetic Polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) Pharmacokinetics in Leflunomide-Treated Patients with Rheumatoid Arthritis. *Petra Bohanec Grabar, Iztok Grabnar, Blaž Rozman, Dušan Logar, Matija Tomšič, Daša Šuput, Tina Trdan, Lucija Peterlin Mašič, Aleš Mrhar, and Vita Dolžan* . . . . . **2061**

24-Hydroxycholesterol Sulfation by Human Cytosolic Sulfotransferases: Formation of Monosulfates and Disulfates, Molecular Modeling, Sulfatase Sensitivity, and Inhibition of Liver X Receptor Activation. *Ian T. Cook, Zofia Duniec-Dmuchowski, Thomas A.*

Continued on next page

<i>Kocarek, Melissa Runge-Morris, and Charles N. Falany</i> . . . . .	<b>2069</b>	<i>Nobuyuki Koga, Shizuo Yamada, and Masakuni Degawa</i> . . . . .	<b>2095</b>
Further Studies on the Role of Metabolites in ( $\pm$ )-3,4-Methylenedioxymethamphetamine-Induced Serotonergic Neurotoxicity. <i>Melanie Mueller, Jie Yuan, Anne Felim, Anne Neudörffer, Frank T. Peters, Hans H. Maurer, Una D. McCann, Martine LARGERON, and George A. Ricaurte</i> . . . . .	<b>2079</b>	Construction of Triple-Transfected Cells [Organic Anion-Transporting Polypeptide (OATP) 1B1/Multidrug Resistance-Associated Protein (MRP) 2/MRP3 and OATP1B1/MRP2/MRP4] for Analysis of the Sinusoidal Function of MRP3 and MRP4. <i>Masakazu Hirouchi, Hiroyuki Kusuhara, Reiko Onuki, Brian W. Ogilvie, Andrew Parkinson, and Yuichi Sugiyama</i> . . . . .	<b>2103</b>
▣ Hepatic Cytochrome P450 Enzyme Alterations in Humans with Progressive Stages of Nonalcoholic Fatty Liver Disease. <i>Craig D. Fisher, Andrew J. Lickteig, Lisa M. Augustine, James Ranger-Moore, Jonathan P. Jackson, Stephen S. Ferguson, and Nathan J. Cherrington</i> . . . . .	<b>2087</b>	<b>ACCELERATED COMMUNICATION</b>	
		▣ MicroRNAs Regulate CYP3A4 Expression via Direct and Indirect Targeting. <i>Yu-Zhuo Pan, Wenqing Gao, and Ai-Ming Yu</i> . . . . .	<b>2112</b>
		<b>ERRATUM</b>	
4-Hydroxy-2,2',3,4',5,5',6-heptachlorobiphenyl-Mediated Decrease in Serum Thyroxine Level in Mice Occurs through Increase in Accumulation of Thyroxine in the Liver. <i>Yoshihisa Kato, Koichi Haraguchi, Makiko Kubota, Yoshiki Seto, Shin-ichi Ikushiro, Toshiyuki Sakaki,</i>		Correction to "Characterization of Dasatinib and its Structural Analogs as CYP3A4 Mechanism-Based Inactivators and the Proposed Bioactivation Pathways". . . . .	<b>2118</b>

▣ Supplemental material is available online at <http://dmd.aspetjournals.org>.

*About the cover:* Involvement of miRNAs in the regulation of *CYP3A4* expression. See article by Pan et al. on page 2112 of this issue.